Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Aranesp, Epogen Share In CKD, ESRD Will Remain Stable Despite Hemoglobin Targets – JP Morgan

This article was originally published in The Pink Sheet Daily

Executive Summary

After surveying nephrologists, JP Morgan analysts predict that use of the erythropoiesis-stimulating agents in kidney disease settings will not change dramatically.

You may also be interested in...



Genentech Moves To Dampen Avastin Use In Wet AMD By Limiting Sales To Compounding Pharmacists

As of Nov. 30, Avastin can no longer be purchased by compounding pharmacists from wholesale distributors, company announces in "Dear Retinal Community Member" letter.

Genentech Moves To Dampen Avastin Use In Wet AMD By Limiting Sales To Compounding Pharmacists

As of Nov. 30, Avastin can no longer be purchased by compounding pharmacists from wholesale distributors, company announces in "Dear Retinal Community Member" letter.

ESA Committee Review To Focus On Hemoglobin Target For Kidney Disease

FDA advisory panel will also be asked to discuss management of non-responders at increased risk for cardiovascular harm.

Related Content

Topics

UsernamePublicRestriction

Register

OM010563

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel